BRAF inhibitors (BRAFi) (vemurafenib, dabrafenib, encorafenib) and also mitogen-activated protein kinase (MEK) inhibitors (MEKi) (trametinib, binimetinib) represent effective and promising therapeutic approaches in patients with relapsed/refractory HCL. The gene discussed is WNK2; the disease is hairy cell leukemia.